Expression of toll-like receptors, pro-, and antiinflammatory cytokines in relation to gut microbiota in irritable bowel syndrome: The evidence for its micro-organic basis

Journal of Neurogastroenterology and Motility

Volumn 24, Issue 4, 2018, Pages 628-642

  Shukla, Ratnakar ^a   Ghoshal, Ujjala ^a   Ranjan, Prabhat ^a   Ghoshal, Uday C ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytokines; Immunohistochemistry; Lipopolysaccharide; Peptidoglycan; Toll like receptors

Indexed keywords

EID: 85054679639     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm18130     Document Type: Article

References (54)

1. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085.
2. Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian society of gastroenterology task force. Indian J Gastroenterol 2008;27:22-28.
3. Shukla R, Ghoshal U, Dhole TN, Ghoshal UC. Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis. Dig Dis Sci 2015;60:2953-2962.
4. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011;106:329-336.
5. Hajela N, Ramakrishna BS, Nair GB, Abraham P, Gopalan S, Ganguly NK. Gut microbiome, gut function, and probiotics: implications for health. Indian J Gastroenterol 2015;34:93-107.
6. Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36-49.
7. Ortiz-Lucas M, Saz-Peiró P, Sebastián-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. Rev Esp Enferm Dig 2010;102:711-717.
8. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012;7:e42777.
9. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010;10:131-144.
10. Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial tolllike receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 2008;83:493-498.
11. Cario E. Bacterial interactions with cells of the intestinal mucosa: toll-like receptors and NOD2. Gut 2005;54:1182-1193.
12. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1045-1052.
13. Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R. [How the intricate interaction among toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology.] J Immunol Res 2015;2015:489821. [Chinese]
14. Dillon S, Agrawal A, Van Dyke T, et al. A toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signalregulated kinase mitogen-activated protein kinase and c-fos in dendritic cells. J Immunol 2004;172:4733-4743.
15. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Activation profile of toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010;159:11-22.
16. Liu Z, Chen X, Wang X, et al. Chemokine CXCL11 links microbial stimuli to intestinal inflammation. Clin Exp Immunol 2011;164:396-406.
17. Tokuyama H, Ueha S, Kurachi M, et al. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfatemediated colitis. Int Immunol 2005;17:1023-1034.
18. Danese S, Gao B. Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases. Gut 2010;59:149-151.
19. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2014;26:1036-1048.
20. Ghoshal UC, Gwee KA, Chen M, et al. Development, translation and validation of enhanced asian rome III questionnaires for diagnosis of functional bowel diseases in major asian languages: a rome foundationasian neurogastroenterology and motility association working team report. J Neurogastroenterol Motil 2015;21:83-92.
21. Xu J, Yang Y, Sun J, et al. Expression of toll-like receptors and their association with cytokine responses in peripheral blood mononuclear cells of children with acute rotavirus diarrhoea. Clin Exp Immunol 2006;144:376-381.
22. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR. toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 2004;112:428-436.
23. Jin SH, Kang HY. Activation of toll-like receptors 1, 2, 4, 5, and 7 on human melanocytes modulate pigmentation. Ann Dermatol 2010;22:486-489.
24. Zhou Y, Wei Y, Wang L, et al. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol 2011;10:2.
25. Hida N, Shimoyama T Jr, Neville P, et al. Increased expression of IL-10 and IL-12 (p40) mRNA in Helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration. J Clin Pathol 1999;52:658-664.
26. Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1882-1890.
27. Kimang'a A, Revathi G, Kariuki S, et al. IL-17A and IL-17F gene expression is strongly induced in the mucosa of H. pylori-infected subjects from Kenya and Germany. Scand J Immunol 2010;72:522-528.
28. Stanislawowski M, Wierzbicki PM, Golab A, et al. Decreased toll-like receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients. J Physiol Pharmacol 2009;60(suppl 4):71-75.
29. Liang WJ, Zhang G, Luo HS, Liang LX, Huang D, Zhang FC. Tryptase and protease-activated receptor 2 expression levels in irritable bowel syndrome. Gut Liver 2016;10:382-390.
30. Ipci K, Altintoprak N, Muluk NB, Senturk M, Cingi C. The possible mechanisms of the human microbiome in allergic diseases. Eur Arch Otorhinolaryngol 2017;274:617-626.
31. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7017.
32. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci USA 2011;108(suppl 1):4607-4614.
33. McKernan DP, Nolan A, Brint EK, et al. Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS One 2009;4:e8226.
34. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003;170:5165-5175.
35. Thompson-Chagoyán OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 2005;24:339-352.
36. Darkoh C, Comer L, Zewdie G, Harold S, Snyder N, Dupont HL. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One 2014;9:e93144.
37. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013;108:1066-1074.
38. Chang L, Sundaresh S, Elliott J, et al. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil 2009;21:149-159.
39. Jardí F, Fernández-Blanco JA, Martínez V, Vergara P. Plasticity of dorsal root ganglion neurons in a rat model of post-infectious gut dysfunction: potential implication of nerve growth factor. Scand J Gastroenterol 2014;49:1296-1303.
40. Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012;107:262-272.
41. De Silva AP, Nandasiri SD, Hewavisenthi J, et al. Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol 2012;47:619-624.
42. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-α and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-2516.
43. Geiger B, Wenzel J, Hantschke M, Haase I, Ständer S, von Stebut E. Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells. Br J Dermatol 2010;162:870-874.
44. Bao CR, Tang GY, Zhang XP, Quan ZW. Lentivirus-mediated gene transfer of small interfering RNA against the chemokine receptor CXCR3 suppresses cytokine indicators of acute graft rejection in a rat model. J Int Med Res 2010;38:1113-1120.
45. Keszthelyi D, Troost FJ, Jonkers DM, et al. Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:392-402.
46. Arebi N, Gurmany S, Bullas D, Hobson A, Stagg A, Kamm M. Review article: the psychoneuroimmunology of irritable bowel syndrome - an exploration of interactions between psychological, neurological and immunological observations. Aliment Pharmacol Ther 2008;28:830-840.
47. Taché Y, Martinez V, Wang L, Million M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 2004;141:1321-1330.
48. Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-382.
49. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009;15:2887-2892.
50. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol 2009;44:26-46.
51. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.
52. Seth AK, Rawal P, Bagga R, Jain P. Successful colonoscopic fecal microbiota transplantation for active ulcerative colitis: first report from India. Indian J Gastroenterol 2016;35:393-395.
53. Subramanyam C, Pratap N, Gandham P, et al. Influence of probiotic administration on the fecal microbiota in diarrhea-predominant irritable bowel syndrome. Indian J Gastroenterol 2015;34:275-276.
54. Vaishnavi C. Fecal microbiota transplantation for management of Clostridium difficile infection. Indian J Gastroenterol 2014;33:301-307.